Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates
05 mai 2021 16h05 HE
|
Sana Biotechnology, Inc
Presented key proof of concept data for multiple platforms at AACR 2021 Q1 2021 cash position of $981.9 million SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a...
Sana Biotechnology to Present at the BofA Securities 2021 Healthcare Conference
04 mai 2021 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021
27 avr. 2021 16h35 HE
|
Sana Biotechnology, Inc
— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes — SEATTLE, April 27, 2021 (GLOBE NEWSWIRE)...
Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
09 avr. 2021 09h00 HE
|
Sana Biotechnology, Inc
– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogenresults in tumor eradication –– Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in...
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
24 mars 2021 16h10 HE
|
Sana Biotechnology, Inc
Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of $412 million Further strengthened cash position with $627 million in net IPO proceeds SEATTLE,...
FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies
17 mars 2021 09h00 HE
|
Sana Biotechnology, Inc; FUJIFILM Cellular Dynamics, Inc.
MADISON, Wis. and SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC)...
Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
08 févr. 2021 17h24 HE
|
Sana Biotechnology, Inc
SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its...
Sana Announces Upsized Pricing of Initial Public Offering
03 févr. 2021 23h22 HE
|
Sana Biotechnology, Inc
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of...